Condition: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer · Sponsor: OncoTherapy Science, Inc.
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Norwalk Hospital | Norwalk, Connecticut, United States | Completed |
| Emory University, Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Kapi'olani Medical Center for Women & Children | Honolulu, Hawaii, United States | Recruiting |
| Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center | Lebanon, New Hampshire, United States | Recruiting |
| Weill Cornell Medicine | NewYork-Presbyterian | New York, New York, United States | Completed |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Completed |
| MD Anderson Cancer Center | Houston, Texas, United States | Completed |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02926690